NCT03850873View on ClinicalTrials.gov

A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2021

Conditions
Advanced Breast Cancer
Interventions
DRUG

TQB3616

TQB3616 administerde days 28 of a 28-day schedule,doses ranging from 20m，40mg，60mg，80mg，100mg，120mg once daily

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY